These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 36899326)
1. Reactogenicity within the first week after Sinopharm, Sputnik V, AZD1222, and COVIran Barekat vaccines: findings from the Iranian active vaccine surveillance system. Enayatrad M; Mahdavi S; Aliyari R; Sahab-Negah S; Nili S; Fereidouni M; Mangolian Shahrbabaki P; Ansari-Moghaddam A; Heidarzadeh A; Shahraki-Sanavi F; Fateh M; Khajeha H; Emamian Z; Behmanesh E; Sheibani H; Abbaszadeh M; Jafari R; Valikhani M; Binesh E; Vahedi H; Chaman R; Sharifi H; Emamian MH BMC Infect Dis; 2023 Mar; 23(1):150. PubMed ID: 36899326 [TBL] [Abstract][Full Text] [Related]
2. Adverse effects following COVID-19 vaccination in Iran. Babaee E; Amirkafi A; Tehrani-Banihashemi A; SoleimanvandiAzar N; Eshrati B; Rampisheh Z; Asadi-Aliabadi M; Nojomi M BMC Infect Dis; 2022 May; 22(1):476. PubMed ID: 35585518 [TBL] [Abstract][Full Text] [Related]
3. Study protocol: cohort event monitoring for safety signal detection after vaccination with COVID-19 vaccines in Iran. Aliyari R; Mahdavi S; Enayatrad M; Sahab-Negah S; Nili S; Fereidooni M; Mangolian Shahrbabaki P; Ansari-Moghaddam A; Heidarzadeh A; Shahraki-Sanavi F; Amini Moridani M; Fateh M; Khajeha H; Emamian Z; Behmanesh E; Sharifi H; Emamian MH BMC Public Health; 2022 Jun; 22(1):1153. PubMed ID: 35681132 [TBL] [Abstract][Full Text] [Related]
4. Effectiveness of COVID-19 vaccines on hospitalization and death in Guilan, Iran: a test-negative case-control study. Heidarzadeh A; Amini Moridani M; Khoshmanesh S; Kazemi S; Hajiaghabozorgi M; Karami M Int J Infect Dis; 2023 Mar; 128():212-222. PubMed ID: 36572376 [TBL] [Abstract][Full Text] [Related]
5. Signs, Symptoms, and Side-Effects Presented by Different Types of COVID-19 Vaccines: A Prospective Cohort Study. Zare Z; Assarroudi A; Armat MR; Laal Ahangar M; Estaji M; MoghaddamHosseini V; Dianatinasab M Life (Basel); 2022 Dec; 12(12):. PubMed ID: 36556411 [TBL] [Abstract][Full Text] [Related]
6. A prospective cohort study protocol: monitoring and surveillance of adverse events following heterologous booster doses of Oxford AstraZeneca COVID-19 vaccine in previous recipients of two doses of Sinopharm or Sputnik V vaccines in Iran. Soltani S; Matin BK; Gouya MM; Zahraei SM; Moradi G; Chehri O; Soofi M; Moradinazar M; Shadmani FK; Kalantari M; Khajeha H; Emamian MH; Najafi F BMC Public Health; 2023 Jul; 23(1):1415. PubMed ID: 37488541 [TBL] [Abstract][Full Text] [Related]
7. Comparison of the immunogenicity of five COVID-19 vaccines in Sri Lanka. Jeewandara C; Aberathna IS; Danasekara S; Gomes L; Fernando S; Guruge D; Ranasinghe T; Gunasekera B; Kamaladasa A; Kuruppu H; Somathilake G; Jayamali J; Jayathilaka D; Wijayatilake HDK; Pushpakumara PD; Harvie M; Nimasha T; de Silva SDG; Wijayamuni R; Schimanski L; Rijal P; Tan J; Townsend A; Ogg GS; Malavige GN Immunology; 2022 Oct; 167(2):263-274. PubMed ID: 35751563 [TBL] [Abstract][Full Text] [Related]
8. Side effects of Sputnik V, Oxford-AstraZeneca, Sinopharm, and Covaxin and their associations with other variables among healthcare workers of a tertiary hospital in Iran. Oghazian S; Tavanaei Tamanaei T; Haghighi R; Faregh M; Oghazian MB Int Immunopharmacol; 2023 Apr; 117():109784. PubMed ID: 36812676 [TBL] [Abstract][Full Text] [Related]
9. Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran. Zare H; Rezapour H; Mahmoodzadeh S; Fereidouni M Int Immunopharmacol; 2021 Dec; 101(Pt B):108351. PubMed ID: 34801416 [TBL] [Abstract][Full Text] [Related]
10. Comparative immunogenicity and safety of Gam-COVID-Vac and Sinopharm BBIBP-CorV vaccines: results of a pilot clinical study. Stoma I; Korsak K; Voropaev E; Osipkina O; Kovalev A Heliyon; 2023 Nov; 9(11):e21877. PubMed ID: 38027828 [TBL] [Abstract][Full Text] [Related]
11. Short-term Side Effects of COVID-19 Vaccines (Astrazeneca, Sputnik-V, and Sinopharm) in Health Care Workers: A Cross-Sectional Study in Iran. Azimi-Nezhad M; Gholami A; Taghiabadi E; Ghodsi H Med J Islam Repub Iran; 2022; 36():159. PubMed ID: 36721491 [No Abstract] [Full Text] [Related]
12. Potential Adverse Effects of COVID-19 Vaccines on Iranian Healthcare Workers: Comparison of Four Available Vaccines in Tehran: A Retrospective Cross-sectional Study. Abdollahi A; Naseh I; Kalroozi F; Kazemi-Galougahi MH; Nezamzadeh M; Qorbanzadeh A; Ameri R; Taghavi H; Zoshk MY Oman Med J; 2023 Mar; 38(2):e486. PubMed ID: 37168286 [TBL] [Abstract][Full Text] [Related]
13. COVID-19 cases, hospitalizations and deaths after vaccination: a cohort event monitoring study, Islamic Republic of Iran. Hosseinzadeh A; Sahab-Negah S; Nili S; Aliyari R; Goli S; Fereidouni M; Alami A; Shati M; Ahmadnezhad E; Mehravaran S; Fateh M; Khajeha H; Emamian Z; Behmanesh E; Mahdavi S; Enayatrad M; Mangolian Shahrbabaki P; Ansari-Moghaddam A; Heidarzadeh A; Shahraki-Sanavi F; Hashemi Shahri SM; Dehghan M; Amini Moridani M; Sheibani H; Abbaszadeh M; Jafari R; Valikhani M; Binesh E; Vahedi H; Chaman R; Khodashahi R; Amini M; Jabbari Azad F; Rezaeitalab F; Amel Jamehdar S; Eshraghi A; Sharifi H; Hashemi Bajgani SM; Mahdavi A; Jafarzadeh A; Farokhnia M; Ebrahimi S; Pardakhti A; Ghaderi E; Soltani H; Jadidoleslami S; Arianejad A; Gavili H; Moradveisi B; Motamedi D; Zare H; Kazemi T; Emamian MH Bull World Health Organ; 2022 Aug; 100(8):474-483. PubMed ID: 35923277 [TBL] [Abstract][Full Text] [Related]
14. Active Safety Surveillance of Four Types of COVID-19 Vaccines: A National Study from Jordan. Abdel-Qader DH; Abdel-Qader H; Silverthorne J; Kongkaew C; Al Meslamani AZ; Hayajneh W; Ata OMA; Shnaigat W; AbuRuz S; Al Nsour M; Alhariri A; Shnewer K; Da'ssan M; Obeidat NM; Nusair KE; Jalamdeh MS; Hawari F; Khader K; Hakim T; Hammad FA; Al Qudah M; Asad M Clin Drug Investig; 2022 Oct; 42(10):813-827. PubMed ID: 35999428 [TBL] [Abstract][Full Text] [Related]
15. Personalized predictions of adverse side effects of the COVID-19 vaccines. Jamshidi E; Asgary A; Kharrazi AY; Tavakoli N; Zali A; Mehrazi M; Jamshidi M; Farrokhi B; Maher A; von Garnier C; Rahi SJ; Mansouri N Heliyon; 2023 Jan; 9(1):e12753. PubMed ID: 36597482 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness of Coronavirus Disease 2019 Vaccines in Preventing Infection, Hospital Admission, and Death: A Historical Cohort Study Using Iranian Registration Data During Vaccination Program. Mirahmadizadeh A; Heiran A; Bagheri Lankarani K; Serati M; Habibi M; Eilami O; Heiran F; Moghadami M Open Forum Infect Dis; 2022 Jun; 9(6):ofac177. PubMed ID: 35615300 [TBL] [Abstract][Full Text] [Related]
17. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: a preliminary report of COV006, a phase 2 single-blind, randomised, controlled trial. Li G; Cappuccini F; Marchevsky NG; Aley PK; Aley R; Anslow R; Bibi S; Cathie K; Clutterbuck E; Faust SN; Feng S; Heath PT; Kerridge S; Lelliott A; Mujadidi Y; Ng KF; Rhead S; Roberts H; Robinson H; Roderick MR; Singh N; Smith D; Snape MD; Song R; Tang K; Yao A; Liu X; Lambe T; Pollard AJ; Lancet; 2022 Jun; 399(10342):2212-2225. PubMed ID: 35691324 [TBL] [Abstract][Full Text] [Related]
18. Immunogenicity and adverse events of the COVID-19 vaccines in healthy and individuals with autoimmune diseases in an Iranian population. Moradi Hasan-Abad A; Arbabi M; Gilasi H; Motedayyen H Int J Immunopathol Pharmacol; 2024; 38():3946320241239202. PubMed ID: 38494849 [No Abstract] [Full Text] [Related]
19. Evaluation of short-term adverse events of COVID-19 vaccines: An observational study. Fathi F; Ameri A; Safa O; Hassaniazad M; Fathalipour M Medicine (Baltimore); 2024 Feb; 103(8):e35549. PubMed ID: 38394514 [TBL] [Abstract][Full Text] [Related]
20. Adverse events and SARS-CoV-2 antibody responses after immunization with Sputnik V, ChAdOx1-S, and BBIBP-CorV vaccines in people with HIV. Mauas R; Urueña A; Cecchini D; Strada ML; Arietti S; Cassetti I; Nogueira NF; Salazar AS; Rodriguez VJ; Jones DL; Alcaide ML AIDS; 2023 May; 37(6):941-946. PubMed ID: 36728228 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]